Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Turning Point Therapeutics Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Turning Point Therapeutics Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 13 Jun 2019 | Lorem |
| Turning Point’s repotrectinib likely limited to later-line uptake in a crowded ROS1+ NSCLC space despite significant Phase I data, experts say | 13 Jun 2019 | Manasi Vaidya |
| Pfizer’s Lorbrena in ROS1+ NSCLC Xalkori-treated patients to be presented in September at World Conference on Lung Cancer, source says | 05 Jun 2019 | Manasi Vaidya |
| TP Therapeutics aims to submit Phase I data for anticancer agent TPX-0005 to ASCO 2018 - CEO | 13 Dec 2017 | Manasi Vaidya |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer